GOSWAMI JOYDEEP
Known title: DirectorCIK: 0001533115
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Transaction History
| BLFS | ▼ Sell | Other | 53,156 | — | 10/6/2026 | View on chart |
| BLFS | ▲ Buy | Grant | 8,170 | — | 2/24/2026 | View on chart |
| BLFS | ▼ Sell | Open Market | 1,666 | $48K | 10/24/2025 | View on chart |
| BLFS | ▼ Sell | Open Market | 1,334 | — | 10/16/2025 | View on chart |
| BLFS | ▲ Buy | Grant | 6,876 | — | 3/18/2025 | View on chart |
| BLFS | ▲ Buy | Grant | 11,264 | — | 3/8/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 5,569 | $0 | 3/5/2024 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,887 | $213K | 11/5/2023 | View on chart |
| BLFS | ▲ Buy | Grant | 577 | — | 11/1/2023 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 165 | $23K | 10/5/2023 | View on chart |
| BLFS | ▲ Buy | Grant | 422 | — | 10/1/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 10,074 | $0 | 3/1/2023 | View on chart |
| ILMN | ▲ Buy | Option Exercise | 4,696 | $0 | 2/21/2023 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,640 | $333K | 2/21/2023 | View on chart |
| BLFS | ▲ Buy | Grant | 10,187 | — | 1/3/2023 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 638 | $139K | 11/5/2022 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 165 | $36K | 10/5/2022 | View on chart |
| BLFS | ▲ Buy | Grant | 280 | — | 8/1/2022 | View on chart |
| BLFS | ▲ Buy | Grant | 369 | — | 7/1/2022 | View on chart |
| BLFS | ▲ Buy | Grant | 343 | — | 6/1/2022 | View on chart |
| BLFS | ▲ Buy | Grant | 14,730 | — | 5/6/2022 | View on chart |
| ILMN | ▲ Buy | Grant | 2,082 | $0 | 3/1/2022 | View on chart |
| ILMN | ▲ Buy | Option Exercise | 3,979 | $0 | 2/22/2022 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,521 | $487K | 2/22/2022 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 264 | $108K | 11/5/2021 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 115 | $45K | 10/5/2021 | View on chart |
| BLFS | ▲ Buy | Grant | 2,938 | — | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analyst Pieces Highlight BioLife Solutions' Customer Retention, Momentum
Two analyst pieces this week focused on BioLife Solutions. Diamond Hill pointed to the company's high switching costs, suggesting customers face barriers to moving to competitors, which can support steady revenue. ChartMill separately noted the stock shows strong growth momentum along with a potential breakout setup. The stock is trading near the lower end of its 52-week range, while analysts maintain an average price target around $31, well above current levels.
Analyst Pieces Highlight BioLife Solutions' Customer Retention, Momentum. Two analyst pieces this week focused on BioLife Solutions. Diamond Hill pointed to the company's high switching costs, suggesting customers face barriers to moving to competitors, which can support steady revenue. ChartMill separately noted the stock shows strong growth momentum along with a potential breakout setup. The stock is trading near the lower end of its 52-week range, while analysts maintain an average price target around $31, well above current levels.